# Different risk factors for bleeding and discontinuation between dabigatran and rivaroxaban

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/different-risk-factors-for-bleeding-and-discontinuation-between-dabigatran-and/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Masami Nishino,Naotaka Okamoto,Akihiro Tanaka,Naoki Mori,Masahiko Hara,Masamichi Yano,Nobuhiko Makino,Yasuyuki Egami,Ryu Shutta,Jun Tanouchi |
| Citations | 14 |
| DOI | 10.1016/j.jjcc.2015.08.019 |
| Fields | Medicine,Nursing |
| Open Access | true |
| OA Status | bronze |
| OA URL | http://www.journal-of-cardiology.com/article/S0914508715002841/pdf |
| OpenAlex ID | https://openalex.org/W2220556496 |
| PMID | 26443373 |
| Type | article |
| Year | 2015 |

## Paper authors

- [Naoki Mori](https://scholariq.org/researchers/naoki-mori/)

## Paper primary topic

- [Atrial Fibrillation Management and Outcomes](https://scholariq.org/topics/atrial-fibrillation-management-and-outcomes/)

## Paper topics

- [Atrial Fibrillation Management and Outcomes](https://scholariq.org/topics/atrial-fibrillation-management-and-outcomes/)
- [Venous Thromboembolism Diagnosis and Management](https://scholariq.org/topics/venous-thromboembolism-diagnosis-and-management/)
- [Vitamin K Research Studies](https://scholariq.org/topics/vitamin-k-research-studies/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.